Thromboxane-induced cerebral microvascular rarefaction predicts depressive symptom emergence in metabolic disease
Journal of Applied Physiology · 2024
DOI: 10.1152/japplphysiol.00410.2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Physiology, 2024. Verfasst von Brayden D Halvorson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada. Hauptthemen laut MEDLINE: Metabolic Syndrome, Microvascular Rarefaction, Metabolic Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association (AHA), NIDDK NIH HHS, Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC).
Abstract (Originalsprache)
With clinical studies linking vascular disease risk to depressive symptom emergence, we used obese Zucker rats, a model of chronic metabolic disease, to identify potential mechanistic links between these two negative outcomes. Depressive symptom severity correlated with the extent of cerebrovascular rarefaction, after increased vascular oxidant stress/inflammation and TxA 2 production. Anti-TxA 2 interventions prevasculopathy blunted rarefaction and depressive symptoms, while biosimulation indicated that cerebrovascular rarefaction increased hypoxia within capillary networks as a potential contributing mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada.
- Department of Biomedical Engineering, University of Western Ontario, London, Ontario, Canada.
- Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.
- Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada.
- Department of Kinesiology, University of Western Ontario, London, Ontario, Canada.
- Division of Exercise Physiology, West Virginia University, Morgantown, West Virginia, United States.
ORCID-Profile: Krishna K Singh, Shawn N Whitehead, C W James Melling, Paul D Chantler, Jefferson C Frisbee
Förderung
- American Heart Association (AHA)
- NIDDK NIH HHS
- Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC)
- HHS | National Institutes of Health (NIH)
- Gouvernement du Canada | Canadian Institutes of Health Research
Zitieren
APA
Halvorson, B. D., Bao, Y., Singh, K. K., Frisbee, S. J., Hachinski, V., Whitehead, S. N., Melling, C. W. J., Chantler, P. D., Goldman, D., & Frisbee, J. C. (2024). Thromboxane-induced cerebral microvascular rarefaction predicts depressive symptom emergence in metabolic disease. Journal of Applied Physiology. https://doi.org/10.1152/japplphysiol.00410.2023
Vancouver
Halvorson BD, Bao Y, Singh KK, Frisbee SJ, Hachinski V, Whitehead SN, et al. Thromboxane-induced cerebral microvascular rarefaction predicts depressive symptom emergence in metabolic disease. Journal of Applied Physiology. 2024. doi:10.1152/japplphysiol.00410.2023
BibTeX
@article{Halvorson2024,
author = {Halvorson, Brayden D and Bao, Yuki and Singh, Krishna K and Frisbee, Stephanie J and Hachinski, Vladimir and Whitehead, Shawn N and Melling, C W James and Chantler, Paul D and Goldman, Daniel and Frisbee, Jefferson C},
title = {Thromboxane-induced cerebral microvascular rarefaction predicts depressive symptom emergence in metabolic disease},
journal = {Journal of Applied Physiology},
year = {2024},
doi = {10.1152/japplphysiol.00410.2023}
}
EUVIMED